Details of the Drug

General Information of Drug (ID: DMVRH9C)

Drug Name
Lomefloxacin
Synonyms
LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Bronchitis CA20 Approved [2]
Cystitis GC00 Approved [2]
Urinary tract infection GC08 Approved [2]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 351.35
Logarithm of the Partition Coefficient (xlogp) -0.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
97% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.98 mL/min/kg [5]
Elimination
65% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.2633 micromolar/kg/day [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.04 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 1.64 mg/mL [3]
Chemical Identifiers
Formula
C17H19F2N3O3
IUPAC Name
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
InChI
InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
InChIKey
ZEKZLJVOYLTDKK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3948
ChEBI ID
CHEBI:116278
CAS Number
98079-51-7
DrugBank ID
DB00978
TTD ID
D02KOF
VARIDT ID
DR00507
INTEDE ID
DR0968
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lomefloxacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Lomefloxacin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [10]
Coadministration of a Drug Treating the Disease Different from Lomefloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [11]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [10]
Idarubicin DMM0XGL Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Idarubicin. Acute myeloid leukaemia [2A60] [12]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Arn-509. Acute myeloid leukaemia [2A60] [13]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [14]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Oliceridine. Acute pain [MG31] [15]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Rivastigmine. Alzheimer disease [8A20] [10]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Ivabradine. Angina pectoris [BA40] [13]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Dronedarone. Angina pectoris [BA40] [10]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Cilostazol. Arterial occlusive disease [BD40] [10]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Posaconazole. Aspergillosis [1F20] [10]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Levalbuterol. Asthma [CA23] [17]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Pirbuterol. Asthma [CA23] [17]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Salbutamol. Asthma [CA23] [17]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Formoterol. Asthma [CA23] [18]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [13]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Desipramine. Attention deficit hyperactivity disorder [6A05] [10]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Retigabine. Behcet disease [4A62] [15]
Lomustine DMMWSUL Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [12]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Eribulin. Breast cancer [2C60-2C6Y] [10]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [10]
Thiotepa DMIZKOP Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [12]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Bosutinib. Breast cancer [2C60-2C6Y] [13]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [19]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [18]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [17]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [18]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [18]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Lomefloxacin and Ketoprofen. Chronic pain [MG30] [20]
Capecitabine DMTS85L Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [12]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Isoproterenol. Conduction disorder [BC63] [17]
Mestranol DMG3F94 Moderate Decreased absorption of Lomefloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [21]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Halothane. Corneal disease [9A76-9A78] [10]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Sevoflurane. Corneal disease [9A76-9A78] [10]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Lomefloxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [22]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Pasireotide. Cushing syndrome [5A70] [10]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Osilodrostat. Cushing syndrome [5A70] [11]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Sertraline. Depression [6A70-6A7Z] [10]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Escitalopram. Depression [6A70-6A7Z] [10]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Clomipramine. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Doxepin. Depression [6A70-6A7Z] [10]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [10]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Deutetrabenazine. Dystonic disorder [8A02] [23]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Ingrezza. Dystonic disorder [8A02] [24]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Solifenacin. Functional bladder disorder [GC50] [10]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Ketoconazole. Fungal infection [1F29-1F2F] [10]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [10]
Procarbazine DMIK367 Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [12]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [26]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [27]
Iron DMAP8MV Moderate Decreased absorption of Lomefloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [28]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Lomefloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [10]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Crizotinib. Lung cancer [2C25] [29]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Ceritinib. Lung cancer [2C25] [10]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [12]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Osimertinib. Lung cancer [2C25] [30]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Selpercatinib. Lung cancer [2C25] [31]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Lumefantrine. Malaria [1F40-1F45] [32]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [33]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Primaquine. Malaria [1F40-1F45] [10]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [13]
Fludarabine DMVRLT7 Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [12]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [34]
Mercaptopurine DMTM2IK Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [12]
Cytarabine DMZD5QR Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [12]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Vemurafenib. Melanoma [2C30] [10]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and LGX818. Melanoma [2C30] [35]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Lomefloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [10]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Panobinostat. Multiple myeloma [2A83] [36]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Thalidomide. Multiple myeloma [2A83] [32]
Melphalan DMOLNHF Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [12]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Siponimod. Multiple sclerosis [8A40] [32]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Fingolimod. Multiple sclerosis [8A40] [10]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Ozanimod. Multiple sclerosis [8A40] [37]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Deflazacort. Muscular dystrophy [8C70] [38]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Romidepsin. Mycosis fungoides [2B01] [15]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [39]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [12]
Busulfan DMXYJ9C Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [12]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Promethazine. Nausea/vomiting [MD90] [10]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Lomefloxacin and Bupropion. Nicotine use disorder [6C4A] [40]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Entrectinib. Non-small cell lung cancer [2C25] [13]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Lofexidine. Opioid use disorder [6C43] [10]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Rucaparib. Ovarian cancer [2C73] [10]
Topotecan DMP6G8T Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [12]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Lomefloxacin and Ibuprofen. Pain [MG30-MG3Z] [20]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Triclabendazole. Parasitic worm infestation [1F90] [15]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Pimavanserin. Parkinsonism [8A00] [41]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [42]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Lefamulin. Pneumonia [CA40] [11]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Lomefloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [43]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Degarelix. Prostate cancer [2C82] [13]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and ABIRATERONE. Prostate cancer [2C82] [13]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Enzalutamide. Prostate cancer [2C82] [13]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Bicalutamide. Prostate cancer [2C82] [13]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Lomefloxacin and Salsalate. Rheumatoid arthritis [FA20] [20]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Lomefloxacin and Oxaprozin. Rheumatoid arthritis [FA20] [20]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [38]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Quetiapine. Schizophrenia [6A20] [10]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Aripiprazole. Schizophrenia [6A20] [32]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Iloperidone. Schizophrenia [6A20] [10]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Paliperidone. Schizophrenia [6A20] [10]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Amisulpride. Schizophrenia [6A20] [44]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Asenapine. Schizophrenia [6A20] [10]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Pimozide. Schizophrenia [6A20] [13]
Ifosfamide DMCT3I8 Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [12]
Docetaxel DMDI269 Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [12]
Mitoxantrone DMM39BF Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [12]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Lomefloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [10]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [10]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [13]
Taxol DMUOT9V Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [12]
Doxorubicin DMVP5YE Minor Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Pitolisant. Somnolence [MG42] [10]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [10]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Cabozantinib. Thyroid cancer [2D10] [13]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Papaverine. Tonus and reflex abnormality [MB47] [45]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Procainamide. Ventricular tachyarrhythmia [BC71] [46]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [10]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Lomefloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [10]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Lomefloxacin and Amiodarone. Ventricular tachyarrhythmia [BC71] [46]
⏷ Show the Full List of 126 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013.
2 Lomefloxacin FDA Label
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
8 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
9 Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
10 Canadian Pharmacists Association.
11 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
12 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
15 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
19 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
20 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
21 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
22 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
23 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
24 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
25 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
26 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
27 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
28 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
29 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
31 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
32 Cerner Multum, Inc. "Australian Product Information.".
33 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
34 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
35 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
36 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
38 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
39 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
40 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
41 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
42 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
43 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
44 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
45 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
46 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]